Long-Term Outcomes in Patients Undergoing Consecutive Bioprosthetic Aortic Valve Replacement.
Worldwide, there is increased use of bioprosthetic valves in the aortic position. Part of this increase has been patient-driven for quality of life reasons. More recently, bioprosthetic valves have been chosen by progressively younger patients, with a strategy of performing a valve-in-valve TAVI if the prosthesis should wear out. Thus, a review was undertaken of the present authors' experience with patients whose first two aortic valve replacements (AVRs) were with bioprosthetic valves. Patients receiving consecutive bioprosthetic AVRs at the Green Lane Cardiothoracic Surgical Unit were identified from a departmental database. Data were retrieved from prospective databases, electronic and archived clinical records. Outcomes of interest were overall survival and freedom from a third or more AVR. A total of 267 patients met the inclusion criteria, with a mean follow up of 22.3 years. Concurrent procedures (e.g., coronary artery bypass grafting) were performed in 65.2% of patients that underwent two bioprosthetic AVRs, and in 79.8% of patients undergoing three or more bioprosthetic AVRs. Median survival of the cohort was 31.7 years. Age at operation was the best predictor of needing a third or more AVR. Receiver operating characteristic curve analysis identified that age <45 years at the first operation and <56 years at the second operation were the optimal cut-off point for the likelihood of needing a third or more aortic valve intervention. Overall survival for consecutive bioprosthetic AVRs was remarkably good. Data relating to consecutive bioprosthetic AVRs is of particular interest in the context of TAVI and valve-in-valve TAVI, which will likely significantly increase the number of patients receiving consecutive bioprosthetic valves. However, it must be noted that the majority of patients in this cohort required concurrent cardiac surgical procedures. The study results provided encouraging data for consecutive bioprosthetic AVRs, as well as data that may be of interest in the setting of TAVI being performed in younger cohorts of patients.